Selection and characterisation of binders based on homodimerisation of immunoglobulin VH domains  by Jin, Hulin et al.
Selection and characterisation of binders based on homodimerisation of
immunoglobulin VH domains
Hulin Jin, Jorge Sepu¤lveda, Oscar R. Burrone
International Centre for Genetic Engineering and Biotechnology, Area Science Park, Padriciano 99, 34012 Trieste, Italy
Received 20 August 2003; revised 25 September 2003; accepted 30 September 2003
First published online 20 October 2003
Edited by Giovanni Cesareni
Abstract The antigen-binding surface of antibodies is formed
by the heterodimerisation of the two variable domains of the
light (VL) and heavy (VH) chains. We have previously described
the spontaneous formation of VH dimers (VHD) in both bacte-
ria and mammalian cells. The self-association of a single do-
main produces a homo-VHD, in which the two identical VH
domains generate a unique symmetric surface for antigen bind-
ing that is never found in the normal VL/VH antibody binding
site. We developed a phagemid vector for the construction of
phage display libraries in which a cysteine residue, introduced at
the C-terminus of the only VH cloned, allowed display of homo-
VHDs. Panning of the library on di¡erent proteins yielded anti-
gen speci¢c binders against lysozyme, glutathione S-transferase
and streptavidin. A lysozyme speci¢c homo-VHD was further
characterised with an apparent a⁄nity determined to be
216- 6.6 nM. Importantly, the results showed that its binding
activity was fully dependent on the dimerisation of both identical
VH domains.
0 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The Fv is the smallest antigen-binding antibody fragment,
inheriting both binding speci¢city and a⁄nity from the intact
full antibody and formed by the heterodimeric association of
the two variable domains VL and VH of the light (L) and
heavy (H) chain, respectively. The actual antibody-combining
site (paratope) is formed by six complementarity-determining
regions, three from each V region, also named L1, L2, L3
(from VL) and H1, H2, H3 (from VH) [1^4]. However, their
contributions to the antigen-binding surface are not evenly
distributed. Detailed crystal structure analysis of antigen^anti-
body complexes have revealed that VH domains in general,
and the H3 loop in particular, contribute more to the antigen-
binding surface, and are responsible for most of the molecular
interaction with the antigen [5,6], although each individual
antibody is di¡erent with respect to the contribution of the
di¡erent loops, and in some cases an extra framework loop
may also contribute to antigen binding. In fact, it has been
found in some cases that VH is able to bind to the antigen
even in the absence of its light chain partner [7^9]. In partic-
ular, the larger diversity and binding ability of VH is the result
of a greater variability in the length and sequence, and hence
the shape, of the H3 loop, which is the consequence of the
VDJ recombination occurring during lymphocyte ontogeny.
Furthermore, conformational diversity within a single anti-
body, in which the H3 loop can adopt at least four di¡erent
conformations has also recently been shown [10]. For these
reasons VH domains are excellent candidates for the construc-
tion of novel binders based on dimerisation.
We have recently shown that VH domains can spontane-
ously assemble into dimers (VHDs) that can be e⁄ciently ex-
pressed and secreted from both mammalian cells and bacteria
[11]. However, an interesting aspect of VH dimerisation resides
in the fact that each VH can, in principle, associate with itself
producing homodimers. These homo-VHDs would have a
symmetric surface for antigen binding, a structure that is
never present in the classic VL/VH-based antibody molecules.
We thus wanted to investigate whether we could derive anti-
gen speci¢c binders based on dimerisation of single VH do-
mains. Here we show the selection and characterisation of
such binders, which were derived from a ¢lamentous phage
library constructed to display homo-double chain (dc) VHDs.
In one case we demonstrated that binding was completely
dependent on the participation of the two identical VH do-
mains.
2. Materials and methods
2.1. Bacterial strains
Phage infection and propagation was carried out in strain DH5KFP
(FP/endA1 hsdR17(rk3mkþ) supE44 thi-1 recA1 gyrA (Nalr) relA1 D
(lacZYA-argF) U169 deoR (F80dlacv(lacZ)M15)), purchased from
Gibco BRL. The non-supressor strain HB2151 (K12, ara v(lac-pro),
thi/FPproAþBþ, lackIqzvM15) was used for expression of soluble frag-
ments [12].
2.2. Library construction
The original phagemid pDAN3 [13] was modi¢ed, for display and
expression of dc VH homodimers (homo-dcVHD/pDAN3) by intro-
ducing a linker sequence (encoding Gly-Cys-Gly) between the SV5
and His6 tags. The single VH was cloned into the unique BssHII/
NheI restriction sites. Total RNA (extracted from peripheral blood
lymphocytes from 40 healthy donors) used for the library construction
was kindly provided by A. Bradbury [14]. First strand cDNA was
synthesised by reverse transcription (RT) using random hexamers.
To obtain the human VH fragments, polymerase chain reaction
(PCR) ampli¢cation was carried out with primers previously described
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by Sblattero et al. [15]. The ¢nal PCR products were digested with
BssHII and NheI and ligated into the homo-dcVHD/pDAN3 phage-
mid vector. Ligated DNA was electroporated into the Escherichia Coli
strain DH5KFP.
2.3. Homo-scVHD construction
For the construction of homo-scVHD, speci¢c VH fragment was
ampli¢ed by PCR reaction using appropriate primers to introduce
BssHII/SalI restriction enzyme sites for position 1 and XhoI/NheI
for position 2. Ampli¢ed fragments were digested by the correspond-
ing restriction enzyme, and cloned into the pDAN3 phagemid vector.
2.4. Fingerprinting
VH fragments were ampli¢ed by PCR with primers of M13-reverse
(backward, 5P-aacagctatgaccatg-3P) and Fdseq (forward, 5P-gaattttctg-
tatgagg-3P). PCR products were subsequently digested by BstNI at
60‡C for 2^3 h. The ¢ngerprinting pattern was obtained by analysing
the digestion products in a 2% agarose gel electrophoresis.
2.5. Phage selection and preparation
Phage selection was performed using a homo-VHD library (5U106
cfu) on immobilised lysozyme (from hen egg white, Boehringer), glu-
tathione S-transferase (GST, Sigma), and streptavidin (from Strepto-
myces avidinii, Sigma). The selection was performed as described [14],
starting with approximately 1012 phage particles per cycle. We started
with low-stringency washes, recovering from 106 to 108 phages and
increased the stringency after the 3rd cycle of panning. In the case of
the selection of lysozyme binders, more than 90% of phages recovered
after the last cycle were corresponded to VHD7:6. DH5KFP bacterial
strain was used for the preparation of phages. The bacteria were
freshly cultured in 2UYT, 100 Wg ml31 ampicillin and 2% glucose,
by shaking at 37‡C for approximately 2 h till OD600 reached 0.5.
Helper phage was then added with a ratio of phages:bacteria between
10:1 and 20:1. The mixture was left at 37‡C for 30 min standing with
occasional agitation, followed by 30 min shaking at 100 rpm at 37‡C.
Bacteria were recovered by centrifugation and cultured overnight at
30‡C in fresh 2UYT, 100 Wg ml31 ampicillin supplemented with 25Wg
ml31 kanamycin. Phage particles in the supernatant were collected
and puri¢ed by two rounds of precipitation using PEG solution
(20% polyethylene glycol 6000, Fluka, 2.5 M NaCl).
2.6. Enzyme-linked immunosorbent assay (ELISA) and Western blot
Binding activities of selected binders were performed by ELISA in
96-well Maxisorb Nunc plates coated with di¡erent concentrations of
antigens (0.1^1 Wg ml31). When using PEG-precipitated phages or
soluble expressed proteins, an anti-SV5 tag mouse monoclonal anti-
body was used as ¢rst antibody followed by horseradish peroxidase
(HRP)-conjugated goat anti-mouse IgG(Q) (KPL) and developed with
TMB kit (Pierce). Data was obtained reading at 450 nM. For Western
blots, PEG-precipitated phages (109^1010 phages per lane) or soluble
protein (20^50 ng per lane), were run in a 15% sodium dodecyl sul-
phate^polyacrylamide gel electrophoresis (SDS^PAGE) and subse-
quently transferred to Immobilon1-P transfer membrane (Millipore)
for 2 h at 200 V or overnight at 50 mA. The membrane was blocked
with 4% milk, 0.1% Tween 20 in phosphate-bu¡ered saline (PBS) for
at least 2 h at room temperature, reacted with anti-SV5 mAb and
developed with HRP-conjugated goat anti-mouse IgG(Q) (KPL) fol-
lowed by ECL reagents kit (Amersham Pharmacia Biotech).
2.7. Soluble homo-VHD protein expression and puri¢cation
The HB2151 bacterial strain was used for expression of soluble
homo-VHD. Bacteria were freshly cultured by incubating at 37‡C
with shaking till OD600 reached 0.7. Expression was induced by add-
ing IPTG (to 0.5 mM) and incubated at 30‡C in a shaker (200 rpm)
for at least 4 h. Bacteria pellet was resuspended in PPB bu¡er (200 mg
ml31 sucrose, 1 mM EDTA, 30mM Tris^HCl pH8.0) at 1/40 total
volume for 20 min on ice, centrifuged and the supernatant collected.
The cell pellet was resuspended in 5 mM MgSO4 bu¡er at 1/40 of
total volume, kept on ice for 20 min, and recentrifuged. The super-
natant was collected, combined with the previous one, dialysed
against PBS and applied to a Ni-NTA agarose column (Qiagen) for
puri¢cation. The column was washed with 10 ml 35 mM imidazole
(Riedel-deHae«n) in PBS, and protein eluted with 2 ml 250 mM imi-
dazole in PBS. Quanti¢cation of recovered puri¢ed proteins was car-
ried out using Coomassie-plus protein assay reagent kit (Pierce).
2.8. A⁄nity determination
Determination of binding a⁄nities was based on the ELISA meth-
od of Shigeo Katoh et al. [16]. In this method two 96-well microtitre
plates (Maxisorb, Nunc) are used to determine the concentration of
binder in solution at equilibrium with Ag adsorbed on the surface of
the plates: one plate, P(E), is used for equilibration of the binder
(VHD) at di¡erent known initial concentrations (C0) (from 2U1039
to 2U1036 M), with the plate coated with a ¢xed amount of antigen
(2 Wg lysozyme per well) ; the second plate, P(M), coated with a lower
amount of antigen (0.2 Wg lysozyme per well) is used to determine the
concentration of free binder (C) after incubation to equilibrium (2 h,
at room temperature) in plate P(E). The signal of bound VHD in
plate P(M) was developed using HRP-conjugated goat anti-mouse
IgG(Q) (KPL) and the TMB kit (Pierce). The equation (C03C)/
C=3Kmn(C03C)+KnAmax/v is used for the a⁄nity determination
(where: n, antibody valence= 1 for scVHD; m, considered to be one
in the case of protein antigens; v, volume of the binder in the well ;
Amax, number of total binding sites per well). The value of the asso-
ciation constant K is determined from the slope of the straight line
obtained by plotting (C03C)/C vs. (C03C).
3. Results
3.1. Design and construction of homo-dcVHD phage library
Following our demonstration that VHD are spontaneously
assembled in both bacteria and mammalian cells [11], we
wanted to investigate the ability of single VH domains to
assembly into homo-VHDs and to study their antigen-binding
capacities. For this purpose we modi¢ed a previously reported
vector for phage display of scFvs or scVHDs constructs [13]
by introducing a cysteine residue between the SV5 and the
His6 tags, to facilitate disulphide bond formation in the bac-
terial periplasm (Fig. 1). We also adapted the restriction sites
to accommodate a single VH. In our strategy we took advan-
tage of the presence of an amber codon separating the VH/tag
moiety from pIII. Since the e⁄ciency of amber suppression
(stopCGln) in DH5KFP bacteria is around 50%, two di¡erent
products were expected: VH/SV5/cys/His6/pIII and VH/SV5/
cys/His6. Dimerisation in the bacterial periplasmic fraction
between these two VH domains should produce a covalently
disulphide bond-stabilised homo-VHD, which would be incor-
porated and displayed by the ¢lamentous phage. In addition,
dimerisation of the short product should generate a dcVHD
Fig. 1. Schematic representation of the phagemid constructed for
the selection of homo-VHD. Two proteins can be produced, one of
them fused to the pIII phage protein. Upon association in the peri-
plasmic fraction, disulphide-bonded stabilised VHD can be phage
displayed or produced as soluble dcVHD.
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that could be directly recovered from the culture supernatant
or bacterial periplasmic fraction. In order to select homo-
VHD binders we constructed a phage display library with
human VH obtained by RT-PCR ampli¢cation of total
RNA derived from PBLs of di¡erent healthy donors. The
library obtained had a relatively small size of 5U106 total
colonies. To study the display capability of homo-dcVHDs
on the surface of the phage particle, we randomly picked
colonies from the library for phage production. The puri¢ed
phages were analysed by Western blot under reducing and
non-reducing conditions.
As shown in Fig. 2a, two forms of the pIII fusion protein
could be observed under non-reducing conditions in some, but
not all, of randomly picked clones; the lower band represent-
ing display of the single VH domain while the upper one
corresponded to the covalently bound homo-VHD. As ex-
pected, under reducing conditions, only a band corresponding
to the single VH-pIII fusions was observed (Fig. 2b).
This result suggested that inter-chain disulphide bond-sta-
bilised homo-dcVHDs fused to the pIII phage minor coat
protein could be displayed on the surface of the phage par-
ticle. In addition, expression of soluble homo-dcVHD protein
by di¡erent random clones was con¢rmed by Western blot
analysis of periplasmic fractions, showing both the expected
30 kDa band of the dimer and theV15 kDa of the monomer
(Fig. 2c). However, in one case (clone 8), all the expressed VH
protein detected was stabilised by an inter-chain disulphide
bond, though with a relatively lower level of expression.
3.2. Selection and characterisation of homo-dcVHDs
The constructed phage library was panned against di¡erent
antigens to select homo-VHDs with antigen speci¢c binding
activity. We selected clones against lysozyme (dcVHD7:6),
GST (dcVHDG8), and streptavidin (dcVHDS6), which were
expressed as dimers (Fig. 3a). Binding of the selected homo-
dcVHDs to their corresponding antigens was studied by ELI-
SA. Each homo-dcVHD showed speci¢c interaction to the
corresponding antigen (Fig. 3b). No binding activities were
found for any homo-dcVHD in any of the two formats, to
the other three control proteins. Randomly picked dcVHD
were used as a negative control in ELISA.
Of the three binders, homo-VHD7:6 appeared to have the
strongest binding activity to its antigen, and was the only one
Fig. 2. Western blot analysis of randomly picked phage displayed
VHDs, run under non-reducing and reducing conditions (a and b,
respectively) and the corresponding soluble products (c) analysed in
non-reducing conditions. Mouse anti-SV5 mAb was used in all three
cases.
Fig. 3. Analysis of soluble fractions of selected VHDs in the dc for-
mat. a: VHDs were obtained from periplasmic fractions and ana-
lysed in reducing and non-reducing conditions, as indicated. b: ELI-
SA of the three selected VHDs, reacted with plates coated with
lysozyme (L), GST (G), streptavidin (S), and BSA (B). An irrelevant
VHD was used as control. c: Western blot of the four di¡erent pro-
teins (100 ng each) resolved in a 10% SDS^PAGE for membrane
transfer, and reacted with dcVHD7:6 (2 Wg VHD in 10 ml PBS).
FEBS 27800 7-11-03
H. Jin et al./FEBS Letters 554 (2003) 323^329 325
able to recognise the antigen (lysozyme) in Western blot (Fig.
3c).
The VH sequences of the selected clones (Fig. 4) correspond
to VH families VH3 and VH4 and have H3 of average lengths
(15, 14 and 11 for VHD7:6, VHDG8 and VHDS6, respectively).
However, VHs, from randomly picked clones, corresponding
to other VH families were also found to dimerise (data not
shown).
3.3. Apparent a⁄nity binding of homo-scVHD7:6
To measure the apparent a⁄nity for lysozyme binding,
soluble VHD7:6 was expressed in the single chain (sc) format
with a His6 tag (scVHD7:6). The scVHD7:6 protein was
puri¢ed on a nickel column and visualised in SDS^PAGE
(Coomassie blue staining) as a single band of V31 kDa
(Fig. 5a).
ELISA [16] was used to measure the apparent binding af-
¢nity of homo-scVHD7:6/lysozyme interaction. Fig. 5b shows
the plot from which the apparent a⁄nity, derived from the
slope of the curve, produced a value of 216U 6.6 nM.
3.4. Binding of homo-VHD7:6 is dependent on VH dimerisation
We then wanted to address the important point of the rel-
ative contribution of either one or two of the VH domains to
the formation of the binding site. To con¢rm that the binding
of the homo-VHD to antigen was dependent on the dimerisa-
tion of the two VH domains, we expressed homo-VHD7:6 in
the sc format and designed a domain-shu¥ing experiment to
study whether or not two V7:6H were needed for binding. We
therefore replaced one V7:6H by several randomly picked, non-
relevant VL or VH and expressed them to study their binding
activities (Fig. 6a).
Clones of scFv (VL-V7:6H ) were constructed by subcloning
di¡erent VL fragments into position 1, whereas scVHDs
were constructed with the non-relevant VH either in position
1 (VH-V7:6H ) or position 2 (V
7:6
H -VH). All these clones were
characterised by BstNI ¢ngerprinting, and the expressed pro-
teins analysed by Western blot (Fig. 6b,c).
Analysis of the binding activities of all clones (Fig. 6d)
revealed that, contrary to the highly positive binding of the
two controls homo-VHD7:6, none of them was able to specif-
Fig. 4. DNA and deduced amino acid sequences of the VH domains of selected VHDs. The sequences of the H3 loops are underlined.
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ically recognise the lysozyme antigen, suggesting that the
binding site was indeed formed by self-dimerisation of V7:6H .
To further exclude the possibility that lysozyme-binding
activity of homo-VHD7:6 was the consequence of independent
binding by each single V7:6H subunit within the molecule, we
performed two additional experiments. First, V7:6H was ex-
pressed as a single domain without the terminal cysteine.
The expressed protein did not show any lysozyme-binding
activity (Fig. 7a), suggesting that dissociation of the two
chains in ELISA eliminated the binding site and therefore
antigen binding. In the second type of experiment, we con-
structed a ‘camelised’ [17] sc version of homo-V7:6H (scVHD
7:6-
cml) in which FR2 residues in the interface, G44, L45 and
W47, were mutated into E, R and G, respectively. As shown
in Fig. 7b, this construct was well expressed but completely
unable to bind antigen. Taken together, all these results con-
¢rmed the absolute requirement of the two dimerised identical
V7:6H domains for antigen binding.
4. Discussion
Detailed crystal structure analysis of antigen^antibody
complexes have revealed that VH domains in general, and
the H3 loop in particular, contribute more to the antigen-
binding surface, and are responsible for most of the interac-
tion with the antigen [18,19].
The speci¢c role of H3 in the antibody^antigen interaction
has been supported by the fact that sequence diversity is
highly concentrated in this loop [2,3]. It has been reported
that the diversity of H3 loop is su⁄cient for most antibody
speci¢cities, permitting otherwise identical IgM molecules to
distinguish between a variety of hapten and protein antigens
[6]. It was also found in many cases that the VH is able to
bind to the antigen even in the absence of its light chain
partner [7^9]. Furthermore, libraries of synthetic H3 loops
inserted into a ¢xed scFv platform have been reported to be
a source of antigen speci¢c binders [20]. We have recently
described that immunoglobulin VH domains can associate
into dimers with antigen-binding speci¢city [11]. VHDs can
be formed by either two di¡erent VH fragments (hetero-
VHDs), or by two identical ones (homo-VHDs), as described
in this report. Both of them, however, take advantage of the
spontaneous ability of these fragments to associate between
them as well as of the larger binding capacity and diversity of
VH in relation to VL.
We assume the two VH domains to interact through the
same interface that associates with VL and in the same relative
orientation. This would be similar to the homodimerisation of
L chains, which are known to dimerise through pairing of the
two homologous domains (VL/VL and CL/CL) [21]. VL dimers
with binding activity have also been described [22]. The most
conserved VH residues involved in the VL/VH interface (like
Gly44, Leu45, Glu46, Trp47, hydrophobic48, in FR2 and Trp103,
Gly104, Gly106 in FR4), which are in part of hydrophobic
nature and participate in the large interface surface of 1000^
1700 AY 2, could serve as a platform for VH/VH interaction
[23,24].
To select homo-VHDs, we used a vector that allowed the
formation of an inter-chain disulphide bond to obtain cova-
lently stabilised VH homodimers in the dc format, displayed
through the minor coat protein pIII. The inter-chain disul-
phide bond was achieved by the introduction of a cysteine
residue at the C-terminal to the VH domain. This strategy is
similar to the one applied for the display of Fab on the ¢la-
mentous phage [12,25], although in our system, the two part-
ners were generated from the same transcript. Phage display
of homodimeric peptides fused to the phage major coat pro-
tein pVIII has also been recently reported [26].
We selected antigen speci¢c binders that were expressed as
soluble proteins in both sc and dc formats. In the case of the
dc format, the relative amount of dimer formation was found
to vary among di¡erent clones, possibly re£ecting di¡erences
in the ability of dimerisation of the diverse VH families. In
fact, variability in the relative ability of heterodimerisation
between VL and VH with di¡erent sequences has also been
described [27]. Interestingly, the amino acid sequences of the
three selected VHs have largely maintained the germline se-
quence of the corresponding VH gene segments (two of them
from the family VH3 and one from the family VH4).
The measurement of the apparent relative a⁄nity of the
lysozyme speci¢c VHD was around 200 nM. This a⁄nity,
Fig. 5. A⁄nity determination of the scVHD7:6/lysozyme binding.
a: Coomassie blue staining of the puri¢ed material used to deter-
mine the apparent Kd. b: The value of 216U 6.6 nM was obtained
from the slope of the straight line. C0 and C correspond to the ini-
tial concentration of scVHD and the concentration of free scVHD
in equilibrium, respectively.
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for a binder selected from the dcVHDs phage library with a
diversity of 5U106 is actually promising. In fact, when scFv
or Fab phage libraries contained a larger number (3U107) of
clones, the average a⁄nity of the selected antibodies was in
the 1035^1037 M range [28,29], while when selecting from
libraries with V1010 independent clones, the a⁄nities could
reach the 1038^1039 M range [14,30^32]. In order to address
the question of whether both VH domains of the homo-VHD
participate in the recognition of the antigen (lysozyme), we
designed and performed experiments with three di¡erent types
of constructs: (a) a domain-shu¥ing experiment using the sc
format, in which one of the two V7:6H was replaced by several
irrelevant VHs or VLs, (b) a dc format in which the C-terminal
cysteine was deleted, thus allowing also monomeric interac-
Fig. 6. Domain shu¥ing in scVHD7:6. a: Randomly picked V domains were inserted in either position 1 (VLs or VHs) or position 2 (only VHs)
of scVHD7:6. Fingerprinting (b) and Western blot analysis (c) of the indicated clones. d: ELISA of individual clones on lysozyme-coated plates.
Control corresponds to an irrelevant scVHD clone.
Fig. 7. Binding depends on homodimerisation of V7:6H . a: A dcVHD
7:6 construct with no cysteine was expressed (monomer in Western blot of
non-reducing SDS^PAGE) and its binding activity determined by ELISA. Binding of the sc and dc versions of VHD7:6, as well as an irrelevant
scVHD, was also measured as controls. b: A ‘camelised’ version of the scVHD7:6 (scVHD7:6-cml) was constructed with three substitutions in
FR2 to eliminate interaction between the two VHs. Binding activity was determined by ELISA including, as negative controls, two scVHD
(scVHD7:6=5 and scVHD3=7:6) and, as positive control, the wild-type scVHD7:6.
FEBS 27800 7-11-03
H. Jin et al./FEBS Letters 554 (2003) 323^329328
tions and (c) a ‘camelised’ sc format in which the two V7:6H
would not be associated, yet still linked, thus maintaining the
possible bivalency [17].
If antigen binding were dependent on a single VH domain,
we would have expected binding activity in all three di¡erent
cases. On the contrary, if only V7:6H -associated homodimers
were active binders, we would not see any binding in all three
cases, as it was indeed the case. Hence, we concluded that
binding by VHD7:6 was the consequence of an antigen-bind-
ing surface created by homodimerisation.
The work presented here demonstrated that VH homo-
dimers can be displayed and selected from ¢lamentous phage
libraries. The interesting dimeric structure formed by the as-
sociation of two identical VH domains with a symmetric anti-
gen-binding site provides a novel platform for the construc-
tion of antigen speci¢c binders that could serve as the basis
for recognition of symmetric targets.
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